Phase 3 Readout~month
Phase 3 Topline: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficac
- Company
- Biohaven Ltd. (BHVN)
- Drug
- refractory
- Indication
- Focal Epilepsy
Other upcoming events for BHVN
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.